Publications in collaboration with researchers from Universidad Complutense de Madrid (19)

2024

  1. Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

2022

  1. C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

    International journal of biological sciences, Vol. 18, Núm. 15, pp. 5873-5884

  2. New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells

    Cell Death and Disease, Vol. 12, Núm. 4

  2. C3G protein, a new player in glioblastoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 18

  3. Contribution of c3g and other gefs to liver cancer development and progression

    Hepatoma Research, Vol. 7

2020

  1. C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation

    Cancers, Vol. 12, Núm. 8, pp. 1-22

  2. Coste de eltrombopag y rituximab por paciente respondedor al tratamiento de la trombocitopenia inmune primaria en España

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 44, Núm. 6, pp. 279-287

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

2018

  1. C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation

    Cell Communication and Signaling, Vol. 16, Núm. 1

  2. How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma

    HEPATIC ONCOLOGY, Vol. 5, Núm. 1

2017

  1. C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis

    Oncotarget, Vol. 8, Núm. 67, pp. 110994-111011

2016

  1. C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38α activation, while it impairs tumor growth through p38α-independent mechanisms

    Oncotarget, Vol. 7, Núm. 29, pp. 45060-45078

2015

  1. p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: Role in migration and invasion

    Journal of Biological Chemistry, Vol. 290, Núm. 7, pp. 4383-4397

2013

  1. Met signaling in cardiomyocytes is required for normal cardiac function in adult mice

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1832, Núm. 12, pp. 2204-2215

2012

  1. C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 8, pp. 1366-1377

2011

  1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

    Current Medical Research and Opinion, Vol. 27, Núm. 5, pp. 951-960

2010

  1. C3G down-regulates p38 MAPK activity in response to stress by Rap-1 independent mechanisms: Involvement in cell death

    Cellular Signalling, Vol. 22, Núm. 3, pp. 533-542

2009

  1. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival

    Cellular Signalling, Vol. 21, Núm. 7, pp. 1229-1235